James E. Galvin, MD, MPH

About Me

Conditions and Treatments

dementia, memory disorders, Alzheimer's disease, cognitive disorder, memory loss, Parkinson's disease, lewy body dementia
Learn more about conditions we treat at NYU Langone:
Dementia, Memory Loss, Alzheimer’s Disease



  • Professor, Department of Neurology
  • Professor, Department of Population Health
  • Professor, Department of Psychiatry
  • Clinical Dir COE PBC Memory Eval Treatment
  • Dir of Clin Operations Ctr Excellence Brain Aging

Board Certifications

  • American Board of Psychiatry & Neurology - Neurology

Education and Training

  • 2005
  • MPH from St. Louis University
  • 1997
  • Fellowship, University of Pennsylvania, Pathology
  • 1992
  • MD from Umdnj


Locations and Appointments

2 Insurance Plans Accepted
  • HealthSmart (WTC)
  • Medicare
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.

NYU Pearl Barlow Center for Memory Evaluation and Treatment
145 East 32nd Street, 2nd Floor
New York, NY 10016

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

Dr. Galvin's lab focuses on (1) developing new biomarkers of neurodegenerative disease; (2) early detection of cognitive impairment through culturally sensitive methods; and (3) translating these findings to the community at large by improving knowledge. Currently, there are 7 studies funded as part of this lab:
* Multicultural Community Dementia Screening
The major goals of this project are to provide cross-cultural validation of dementia screening methods and biological validation against imaging and CSF biomarkers of Alzheimer disease and related disorders.
* Alzheimer's Disease Assistance Center
The major goals of this project is to provide clinical services for underserved communities and increase physician awareness of brain aging and dementia related topics.
* Bioantomical Correlates of Cognitive Phenotypes in PD, PC-MCI, and PDD
The major goals of this project define the Mild Cognitive Impairment stage of PD and map out the functional connectome of PD using structural and functional MRI and high density EEG.
* Biomarker Studies of Risk Factors for Cognitive Disorders in Older Adults
The major goals of this project are to screen multicultural communities for common medical illness to determine future risk of dementia and validate with FDG-PET.
* Piloting an Early Intervention Fall Prevention Program for Community-Dwelling Elderly with Dementia
The major goals of this project are to adapt a falls prevention program (C-PROFET) to reduce falls in vulnerable populations.
* Alzheimer's Disease Neuroimaging Initiative
The major goal of this project is to explore MRI, PET and CSF biomarkers that predict diagnosis of Alzheimer disease and conversion from health brain aging to cognitive impairment.
* New York University Family-Focused Aging Interdisciplinary Research Project
The major goal of this project is to test the feasibility and utility of Family Centered Function Focused Care (FC-FFC), a system-level intervention to improve patient- and family-centered health outcomes.

These studies are funded by NIH, Michael J. Fox Foundation, New York State Department of Health, Alzheimer Association, and the Alma and Morris Schapiro Foundation.
Dr. Galvin plans to initiate additional studies that support the goal of his lab.

1. Characterization of the clinical, cognitive,imaging, biochemical and pathological features of Lewy Body Dementias which include Parkinson's disease, Parkinson's dementia and Dementia with Lewy Bodies
2. Studying the interactions between common medical conditions (hypertension, diabetes, lung disease, obesity, frailty) and risk of cognitive impairment
3. Developing effective patient- and family-oriented interventions that improve quality of life and alleviate disease burden


  • Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): A qualitative analysis of clinical studies in patients with Alzheimer's disease

    Alva, G; Cummings, JL; Galvin, JE; Meng, X; Velting, DM 2015; -, International journal of clinical practice — id: 1515742, year: 2015
  • Whipple's Disease Masquerades as Dementia With Lewy Bodies

    Hurth, Kyle; Tarawneh, Rawan; Ghoshal, Nupur; Benzinger, Tammie L S; Clifford, David B; Geschwind, Michael; Morris, John C; Galvin, James E; Schmidt, Robert E; Cairns, Nigel J 2015 Jan-Mar; 85-89, Alzheimer disease & associated disorders — id: 1466382, year: 2015, page: 85, stat: Journal Article
  • Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

    Molinuevo, Jose L; Frolich, Lutz; Grossberg, George T; Galvin, James E; Cummings, Jeffrey L; Krahnke, Tillmann; Strohmaier, Christine 2015; 9-9, Alzheimer's research & therapy — id: 1495832, year: 2015, page: 9, stat: Journal Article
Read All Publications (130)